EU Review Gets Under Way For Curative Vision Loss Gene Therapy
US Filing Of GenSight’s Lumevoq Will Come Later, In H2 2021
GenSight Biologics believes Lumevoq could become the first curative treatment for Leber hereditary optic neuropathy.
You may also be interested in...
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
Vifor Pharma has resubmitted a marketing application for avacopan to the European Medicines Agency – this time for an unconditional approval.
The European Medicines Agency will continue working over the Christmas period so that it can complete its assessment of the newly filed marketing applications for BioNTech/Pfizer’s and Moderna’s COVID-19 vaccines as soon possible.